Incorporated explicitly to harness the intellectual and research advances of University of Florida faculty, OneVax, LLC is a pre-clinical biotechnology company particularly organized around such effrots as they involve type 1 diabetes. Members of the UF Diabetes Institute and the Department of Biomedical Engineering constitute the core membership and provide the scientific direction of the company. The initial business interests of the company have involved the development of novel vaccine formulations that incorporate biomaterials and polymers for applications including multicomponent and time-release drug delivery. A core goal emphasis in the work of the firm is to harness knowledge of the immune system and biomaterials to create a tolerogenic vaccine to prevent and/or reverse type 1 diabetes.
